

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, June 16, 2005

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L9	l7 or L8	9380
<input type="checkbox"/>	L8	L6 and treating adj3 disease	7684
<input type="checkbox"/>	L7	L6 and treating adj3 disorder	5437
<input type="checkbox"/>	L6	phosphatase and human	24072
		<i>DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L5	l2 or L4	3976
<input type="checkbox"/>	L4	L1 and treating adj3 disorder	2794
<input type="checkbox"/>	L3	L1 and treating adj3 disorders	0
<input type="checkbox"/>	L2	L1 and treating disease	1707
<input type="checkbox"/>	L1	phosphatase and human	26530

END OF SEARCH HISTORY

**STN SEARCH**

10/716,489

FILE 'HOME' ENTERED AT 08:45:50 ON 16 JUN 2005

=&gt; FIL STNGUIDE

=&gt; s phosphatase and human

L1 50764 FILE MEDLINE  
L2 25001 FILE CAPLUS  
L3 14869 FILE SCISEARCH  
L4 4237 FILE LIFESCI  
L5 42900 FILE BIOSIS  
L6 35604 FILE EMBASE

TOTAL FOR ALL FILES

L7 173375 PHOSPHATASE AND HUMAN

=&gt; s l7 and treat? and (disease or disorder)

TOTAL FOR ALL FILES

L14 14175 L7 AND TREAT? AND (DISEASE OR DISORDER)

=&gt; s l14 not 2004-2005/py

TOTAL FOR ALL FILES

L21 12200 L14 NOT 2004-2005/PY

=&gt; dup rem l21

L22 7538 DUP REM L21 (4662 DUPLICATES REMOVED)

=&gt;

=&gt; d 1-10 ibib abs

L22 ANSWER 1 OF 7538 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation  
on STN

ACCESSION NUMBER: 2004:198859 SCISEARCH Full-text

THE GENUINE ARTICLE: 773VF

TITLE: Pimecrolimus: A review

AUTHOR: Gupta A K (Reprint); Chow M

CORPORATE SOURCE: Suite 6, 490 Wonderland Rd S, London, ON N6K 1L6, Canada  
(Reprint); Sunnybrook & Womens Coll, Hlth Sci Ctr, Div  
Dermatol, Toronto, ON, Canada; Univ Toronto, Toronto, ON,  
Canada; Mediprobe Labs Inc, Toronto, ON, Canada

COUNTRY OF AUTHOR: Canada

SOURCE: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND  
VENEREOROLOGY, (SEP 2006) Vol. 17, No. 5, pp. 493-503.  
Publisher: BLACKWELL PUBLISHING LTD, 9600 GARSINGTON RD,  
OXFORD OX4 2DG, OXON, ENGLAND.  
ISSN: 0926-9959.

DOCUMENT TYPE: General Review; Journal

LANGUAGE: English

REFERENCE COUNT: 43

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is one of the new classes of immunomodulating macrolactams and was specifically developed for the treatment of inflammatory skin diseases. The interest in pimecrolimus has been substantial because of its significant anti-inflammatory activity and immunomodulatory capabilities and its low systemic immunosuppressive potential. The mechanism of action of pimecrolimus is the blockage of T cell activation. Pimecrolimus (like all ascomycins) is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12. This pimecrolimus-macrophilin complex effectively inhibits the protein phosphatase calcineurin, by preventing calcineurin from dephosphorylating the nuclear factor of activated T cells (NF-AT), a transcription factor. This results in the blockage of signal transduction pathways in T cells and the inhibition of the synthesis of inflammatory cytokines, specifically Th1- and Th2-type cytokines. Pimecrolimus has also been shown to prevent the release of cytokines and pro-inflammatory mediators from mast cells. Several studies have evaluated the effectiveness of pimecrolimus as a treatment for skin diseases. In animal models of allergic contact dermatitis, topical pimecrolimus was found to be effective. In human studies of allergic contact dermatitis pimecrolimus demonstrated significantly more efficacy than the control treatment. As well, the effectiveness of pimecrolimus 0.6% cream was comparable to 0.1% betamethasone-17-valerate; however, pimecrolimus was not associated with any of the side effects characteristic of a topical steroid. Topical application of pimecrolimus is not associated with skin atrophy. Pimecrolimus is effective and safe in both children and adults with atopic dermatitis. When

pimecrolimus 1% cream has been applied to adult atopics, improvement has been observed as early as the first week, with a 72% reduction in severity after 3 weeks. Pharmacokinetic studies have shown very low blood levels of pimecrolimus following topical application, with no accumulation after repeated applications. Following application of pimecrolimus cream occasional transient irritation may be experienced at the application site. Similar results have also been found in children aged 3 months and older following application of pimecrolimus 1% cream. Topical pimecrolimus in psoriasis appears to exhibit a dose-dependent therapeutic effect under semi-occlusive conditions. Pimecrolimus has an enormous potential as a new treatment of inflammatory skin diseases. It has been shown to be effective in atopic and allergic contact dermatitis, with a favorable adverse-effects profile, which includes little effect on the systemic immune response.

L22 ANSWER 2 OF 7538 MEDLINE on STN  
 ACCESSION NUMBER: 2003082608 MEDLINE Full-text  
 DOCUMENT NUMBER: PubMed ID: 12594123  
 TITLE: Zoledronate treatment in active Paget's disease.  
 AUTHOR: Chung G; Keen R W  
 SOURCE: Annals of the rheumatic diseases, (2003 Mar) 62 (3) 275-6.  
 Journal code: 0372355. ISSN: 0003-4967.  
 PUB. COUNTRY: England: United Kingdom  
 DOCUMENT TYPE: (CASE REPORTS)  
 Letter  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200304  
 ENTRY DATE: Entered STN: 20030221  
 Last Updated on STN: 20030410  
 Entered Medline: 20030409

L22 ANSWER 3 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2004:26913 BIOSIS Full-text  
 DOCUMENT NUMBER: PREV200400028085  
 TITLE: N-acetylcysteine in the treatment of non-alcoholic steatohepatitis.  
 AUTHOR(S): Pamuk, Gulsum Emel [Reprint Author]; Sonsuz, Abdullah [Reprint Author]  
 CORPORATE SOURCE: Division of Hepatology, Department of Internal Medicine, Cerrahpapa Medical Faculty, University of Istanbul, Istanbul, Turkey  
 SOURCE: Journal of Gastroenterology and Hepatology, (October 2003) Vol. 18, No. 10, pp. 1220-1221. print.  
 CODEN: JGHEEO. ISSN: 0815-9319.  
 DOCUMENT TYPE: Letter  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 31 Dec 2003  
 Last Updated on STN: 31 Dec 2003

L22 ANSWER 4 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
 ACCESSION NUMBER: 2003:409031 BIOSIS Full-text  
 DOCUMENT NUMBER: PREV200300409031  
 TITLE: Response: Abnormal ALP isoenzyme in children with epilepsy treated with carbamazepine.  
 AUTHOR(S): Verrotti, Alberto [Reprint Author]; Greco, Rita [Reprint Author]; Latini, Giuseppe; Morgese, Guido; Chiarelli, Francesco [Reprint Author]  
 CORPORATE SOURCE: Department of Pediatrics, University of Chieti, Chieti, Italy  
 SOURCE: Epilepsia, (August 2003) Vol. 44, No. 8, pp. 1129. print.  
 ISSN: 0013-9580 (ISSN print).  
 DOCUMENT TYPE: Letter  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 3 Sep 2003  
 Last Updated on STN: 3 Sep 2003

L22 ANSWER 5 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:409030 BIOSIS Full-text  
DOCUMENT NUMBER: PREV200300409030  
TITLE: Abnormal ALP isoenzyme in children with epilepsy  
treated with carbamazepine.  
AUTHOR(S): Okazaki, Toshio [Reprint Author]; Suzuki, Mitsuyuki; Nagai,  
Tatsuo [Reprint Author]  
CORPORATE SOURCE: Department of Forensic Medicine and Science, Graduate  
School of Medicine, Kitasato University, Kitasato,  
Sagamihara-shi, Kanagawa Prefecture, Japan  
SOURCE: Epilepsia, (August 2003) Vol. 44, No. 8, pp. 1128. print.  
ISSN: 0013-9580 (ISSN print).  
DOCUMENT TYPE: Letter  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Sep 2003  
Last Updated on STN: 3 Sep 2003

L22 ANSWER 6 OF 7538 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on  
STN

ACCESSION NUMBER: 2003:421557 BIOSIS Full-text  
DOCUMENT NUMBER: PREV200300421557  
TITLE: Glipizide treatment with short-term alcohol abuse  
resulting in subfulminant hepatic failure.  
AUTHOR(S): Ilario, Marius John-Marc; Turyan, Hach Vladimir; Axiotis,  
Constantine A. [Reprint Author]  
CORPORATE SOURCE: Department of Pathology, Health Science Center at Brooklyn,  
State University of New York, 450 Clarkson Avenue, Box 25,  
Brooklyn, NY, 11203-2098, USA  
axiotism@aol.com  
SOURCE: Virchows Archiv, (July 2003) Vol. 443, No. 1, pp. 104-105.  
print.  
ISSN: 0945-6317.  
DOCUMENT TYPE: Letter  
LANGUAGE: English  
ENTRY DATE: Entered STN: 10 Sep 2003  
Last Updated on STN: 10 Sep 2003

L22 ANSWER 7 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:942767 CAPLUS Full-text  
DOCUMENT NUMBER: 140:40262  
TITLE: Genes expressed in atherosclerotic tissue and their  
use in diagnosis and pharmacogenetics  
INVENTOR(S): Nevins, Joseph; West, Mike; Goldschmidt, Pascal  
PATENT ASSIGNEE(S): Duke University, USA  
SOURCE: PCT Int. Appl., 408 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091391	A2	20031106	WO 2002-XB38221	20021112
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003091391	A2	20031106	WO 2002-US38221	20021112
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
PRIORITY APPLN. INFO.:

US 2002-374547P P 20020423  
US 2002-420784P P 20021024  
US 2002-421043P P 20021025  
US 2002-424680P P 20021108  
WO 2002-US38221 A 20021112

AB Genes whose expression is correlated with an determinant of an atherosclerotic phenotype are provided. Also provided are methods of using the subject atherosclerotic determinant genes in diagnosis and treatment methods, as well as drug screening methods. In addition, reagents and kits thereof that find use in practicing the subject methods are provided. Also provided are methods of determining whether a gene is correlated with a disease phenotype, where correlation is determined using a Bayesian anal. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L22 ANSWER 8 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:2697 CAPLUS Full-text

DOCUMENT NUMBER: 140:53403

TITLE: Methods of using benzothiophenone derivatives to treat cancer or inflammation

INVENTOR(S): Zhang, Zaihui; Daynard, Timothy S.; Kalmar, Gabriel  
Bela

PATENT ASSIGNEE(S): Kinetek Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000314	A1	20031231	WO 2003-CA921	20030618
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-390589P P 20020621

OTHER SOURCE(S): MARPAT 140:53403

AB This invention is directed to the use of certain benzothiophenone derivs. in treating hyperproliferative disorders, e.g., cancer, inflammation, etc. in a mammal. Of particular interest are hyperproliferative disorders associated with cellular modulation of protein phosphorylation states, i.e., altered activity of phosphorylation modifying enzyme(s), e.g. protein kinases and protein phosphatases. In one aspect of the invention, compds. and pharmaceutical compns. of the invention are used to inhibit the activity of PTPN12 and PTPN2; these enzymes have been associated with alterations in the phosphorylation state of cellular proteins.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 9 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1006684 CAPLUS Full-text

DOCUMENT NUMBER: 140:53443

TITLE: Methods and systems for management of Alzheimer's disease

INVENTOR(S): Shalev, Alon

PATENT ASSIGNEE(S): Brainsgate Ltd., Israel

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105658	A2	20031224	WO 2003-IL508	20030613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-388931P	P 20020614
			US 2002-294310	A 20021114

AB A method is provided for the treatment of Alzheimer's disease (AD). The method includes stimulating a sphenopalatine ganglion (SPG) of a subject so that the concentration of a substance in a brain of the subject changes.

L22 ANSWER 10 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855798 CAPLUS Full-text

DOCUMENT NUMBER: 139:333135

TITLE: Combination therapy including a PPAR  $\alpha/\gamma$  dual agonist, and use in the treatment of hyperglycemia, lipid disorders, and obesity in patients with type 2 diabetes or related disorders

INVENTOR(S): Moller, David E.; Wright, Samuel D.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088962	A1	20031030	WO 2003-US11896	20030415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-373091P	P 20020416
			US 2002-387031P	P 20020607

AB The invention provides pharmaceutical compns. comprising a combination of a first drug which is a PPAR $\alpha/\gamma$  dual agonist and a second drug selected from (1) a cholesterol absorption inhibitor, (2) an HMG-CoA reductase inhibitor, (3) a bile acid sequestrant, (4) nicotinyln alc., nicotinic acid, or a salt thereof, (5) a PPAR $\alpha$  agonist, (6) a phenolic antioxidant, (7) an acyl CoA-cholesterol acyltransferase (ACAT) inhibitor, and (8) a cholesterol ester transfer protein (CETP) inhibitor, including pharmaceutically acceptable salts of one or more of the active ingredients, and a pharmaceutically acceptable carrier. Such combinations are useful for treating hyperglycemia, lipid disorders, and obesity in patients who have type 2 diabetes, metabolic syndrome, insulin resistance, and impaired glucose tolerance.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 11-20 ibib abs

L22 ANSWER 11 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:737908 CAPLUS Full-text

DOCUMENT NUMBER: 139:256390  
 TITLE: Transcriptional regulation of protein tyrosine phosphatase PTP-1B gene and its use for drug screening and therapy for diabetes and obesity  
 INVENTOR(S): Fukada, Toshiyuki  
 PATENT ASSIGNEE(S): Cold Spring Harbor Laboratory, USA; Tonks, Nicholas K.  
 SOURCE: PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076634	A2	20030918	WO 2003-EP2552	20030312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2003223975 A1 20031204 US 2003-388215 20030311 PRIORITY APPLN. INFO.: US 2002-363787P P 20020312 US 2002-435587P P 20021220 US 2003-388215 A 20030311				

AB Compsns. and methods relating to PTP1B associated disorders are provided, based on the discovery that a Y-box protein binding site is present as a transcription enhancer sequence in the promoter region situated upstream (i. e., 5' to) of the human PTP1B gene. This site, situated at nucleotides -155 through -132 of the human PTP1B gene, mediates specific binding interactions with the YB-1 transcription regulatory factor, a member of the Y-box family of proteins. YB-1-targeted antisense constructs reduced PTP1B expression levels, providing an alternative to PTP1B active-site directed regulation of PTP1B activity. Increased phosphorylation of insulin receptor was observed in Rat1 cells that were transfected with YB-1 antisense RNA. The invention claims nucleic acid sequences for Y box protein binding site and for transcription factor YB-1. The invention also claims protein sequences for YB-1. The invention further claims methods for use of transcriptional regulation of human PTP-1 gene for screening drugs and for therapeutic treatment of diabetes and obesity. The invention includes use of reporter genes for measuring PTP-1B enhancer activity, antibodies to the Y-box protein, methods for identifying agents that impair binding of a Y-box protein to a PTP-1B gene promoter Y box, and methods for measuring cellular responses to insulin and leptin.

L22 ANSWER 12 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:678608 CAPLUS Full-text  
 DOCUMENT NUMBER: 139:219271  
 TITLE: Modification of defensins and their use in modulating immune response and antimicrobial activity  
 INVENTOR(S): Moss, Joel; Hirayama, Toshiya; Wada, Akiharo; Levine, Rodney L.; Paone, Gregorino  
 PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA; Nagasaki University  
 SOURCE: PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070176	A2	20030828	WO 2003-US4649	20030218
WO 2003070176	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-358504P P 20020219

AB This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. In one embodiment, compns. including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. In one embodiment, a method is provided for modulating an antimicrobial activity. In another embodiment, a method is provided for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.

L22 ANSWER 13 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:634041 CAPLUS Full-text

DOCUMENT NUMBER: 139:173802

TITLE: KDR-associated phosphatase as target for screening of angiogenesis modulators for therapeutic use

INVENTOR(S): Peters, Kevin Gene

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003067220	A2	20030814	WO 2003-US4029	20030207
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003158083	A1	20030821	US 2002-327414	20021220

PRIORITY APPLN. INFO.: US 2002-355125P P 20020208

AB KDR-associated phosphatase is useful as a target to screen for agents useful for the treatment of angiogenesis mediated disorders.

L22 ANSWER 14 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:633897 CAPLUS Full-text

DOCUMENT NUMBER: 139:178697

TITLE: Screening of human monoclonal antibodies against cell surface coreceptor of HIV for diagnosis and therapy

INVENTOR(S): Hua, Shaobing; Pauling, Michelle H.; Zhu, Li

PATENT ASSIGNEE(S): Genetastix Corporation, USA

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE



PATENT ASSIGNEE(S): O.; Waraham, Nicholas J.  
 SOURCE: Incyte Genomics, Inc., USA  
 PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061583 A2		20030731	WO 2003-US1625	20030117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR PRIORITY APPLN. INFO.: US 2002-PV350405 20020118				

AB The invention provides mutated genes for peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) and the glycogen-associated regulatory subunit of protein phosphatase-1 (PPP1R3A), PPAR $\gamma$ FS and PPP1R3AFS, resp., and polynucleotides and proteins of PPAR $\gamma$ FS and PPP1R3AFS that are expressed in diabetes. In particular, frameshift/premature stop mutations in two unlinked genes, PPAR $\gamma$  and PPP1R3A, which are key regulators of lipid metabolism (adipocyte differentiation) and glycogen synthesis (muscle /liver mode of glycogen storage) resp., are found in type II diabetes patients with severe insulin resistance of two families. Specifically, the frameshift/premature stop mutation (A553AAAiT)fs.185(stop 186) in PPAR $\gamma$  results in a mutation of K = lysine to M = methionine at amino acid position 185 of PPAR $\gamma$  within the second zinc-finger (Zn) of the DNA-binding domain (DBD) together with a mutation of S = serine to stop codon (X) at position 186 of PPAR $\gamma$ . And the frameshift/premature stop mutation (C1984AG)fs.662(stop 668) in PPP1R3A results in mutation of an N = asparagine to stop codon at amino acid position 668 of PPP1R3A. The family pedigree shows the concordance of features related to severe insulin resistance and type 2 diabetes and the presence of PPAR $\gamma$  and PPP1R3A mutations. These mutations are confirmed at the protein level by related protein activity assays. Also disclosed are the summaries of clin. and biochem. characteristics of the frameshift mutation carriers for both PPAR $\gamma$ FS and PPP1R3AFS in both family members. Thus, a model of interactions among genes that may underlie common human metabolic disorders such as type 2 diabetes is suggested. It also provides for the use of the DNA mutation, the protein, a polynucleotide encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of diabetes.

L22 ANSWER 17 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:551645 CAPLUS Full-text  
 DOCUMENT NUMBER: 139:80300  
 TITLE: Sequences of a human phosphatidic acid  
 phosphatase 2C sequence homolog and uses in  
 diagnosis, therapy and drug screening  
 INVENTOR(S): Zhu, Zhimin  
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany  
 SOURCE: PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057870	A1	20030717	WO 2003-EP55	20030107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-344798P P 20020107

AB The invention provides protein and cDNA sequences of a novel human phosphatidic acid phosphatase 2C sequence homolog. The invention also provides reagents and methods of regulating a human phosphatidic acid phosphatase 2C sequence homolog. Reagents that regulate human phosphatidic acid phosphatase 2 and reagents which bind to human phosphatidic acid phosphatase 2 gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including cancer, CNS disorders, and COPD.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 18 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:434595 CAPLUS Full-text

DOCUMENT NUMBER: 139:32331

TITLE: Protein-protein interactions involved in signaling by transforming growth factor- $\beta$  or TGF $\beta$  family members and uses thereof

INVENTOR(S): Legrain, Pierre; Gauthier, Jean-Michel; Colland, Frederic; Jacq, Xavier

PATENT ASSIGNEE(S): Hybrigenics, Fr.

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045990 A2		20030605	WO 2002-EP13866	20021126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR			

PRIORITY APPLN. INFO.: US 2001-PV333348 20011126

US 2002-PV384537 20020531

US 2002-PV422471 20021030

AB The present invention relates to protein-protein interactions involved in transforming growth factor- $\beta$  (TGF $\beta$ ) disorders and/or diseases. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, Selected Interacting Domains (SID $\otimes$ ) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins, and pharmaceutical compns. that are capable of modulating the protein-protein interactions. The invention claims polynucleotide and polypeptide sequences for SID $\otimes$  proteins. Some examples show effects of siRNA downregulation or overexpression of SID proteins on TGF $\beta$ - and bone morphogenetic protein-dependent reporter activity.

L22 ANSWER 19 OF 7538 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:417966 CAPLUS Full-text

DOCUMENT NUMBER: 139:5611

TITLE: Mkk3b protein for screening modulators of lymphocyte activation and diagnosing/prognosing/treating disorders associated with lymphocyte dysfunction

INVENTOR(S): Fu, Alan C.; Wu, Jun; Liao, Charlene X.; Mancebo, Helena

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003044529                      A1                      20030530                      WO 2002-US36881                      20021118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:                      US 2001-332441P                      P 20011116

AB                      The present invention provides compns. and methods for modulating lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating lymphocyte activation are provided. Compns. and methods for the treatment of disorders related to lymphocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compns. and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating lymphocyte activation.

REFERENCE COUNT:                      4                      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035871	A1	20030501	WO 2002-JP10882	20021021
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

$$\Rightarrow \log y$$